Study to Evaluate a Subcutaneous Four Months Sustained-Release Formulation of Triptorelin in Patients With Prostate Cancer
This study has been terminated.
(The preliminary data do not support the expected sustainable blood levels of triptorelin for a duration of 4 months in all patients.)
Sponsor:
Ipsen
Information provided by:
Ipsen
ClinicalTrials.gov Identifier:
NCT00415246
First received: December 21, 2006
Last updated: November 15, 2007
Last verified: November 2007
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study has been terminated. |
|---|---|
| Study Completion Date: | October 2007 |
| Estimated Primary Completion Date: | No date given |